The genetics of antiepileptic drug-induced skin reactions

Clinical Pharmacology and Therapeutics

Volumn 89, Issue 6, 2011, Pages 908-910

  Hakimian, S ^a   Miller, J W ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CYTOCHROME P450; HAPTEN; HLA A ANTIGEN; HLA A3101 ANTIGEN; HLA ANTIGEN CLASS 1; HLA B1502 ANTIGEN; HLA C ANTIGEN; HLA DP ANTIGEN; HLA DQ ANTIGEN; HLA DR ANTIGEN; LAMOTRIGINE; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG; ZONISAMIDE;

ARTHRALGIA; ARTICLE; BLISTER; CAUCASIAN; CHINESE; CHROMOSOME 6P; CLINICAL DECISION MAKING; DRESS SYNDROME; DRUG ERUPTION; DRUG EXPOSURE; DRUG HYPERSENSITIVITY; EOSINOPHILIA; ETHNIC GROUP; FEVER; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HAPLOTYPE; HEMATOLOGIC DISEASE; HEPATITIS; HUMAN; IMMUNE RESPONSE; INCIDENCE; INTERSTITIAL NEPHRITIS; JAPANESE; LUNG INFILTRATE; LYMPHADENOPATHY; MACULOPAPULAR RASH; MORBIDITY; MORTALITY; PHARMACOGENETICS; PRIORITY JOURNAL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SKIN ALLERGY; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; URTICARIA;

ANIMALS; ANTICONVULSANTS; EPIDERMAL NECROLYSIS, TOXIC; ETHNIC GROUPS; HUMANS; STEVENS-JOHNSON SYNDROME;

EID: 79956301575     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2010.357     Document Type: Article

References (30)

1. Arif, H. et al. Comparison and predictors of rash associated with 15 antiepileptic drugs. Neurology 68, 1701-1709 (2007). (Pubitemid 46763258)
2. Mockenhaupt, M., Messenheimer, J., Tennis, P. & Schlingmann, J. Risk of Stevens-johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics. Neurology 64, 1134-1138 (2005).
3. Wolf, R., Matz, H., Marcos, B. & Orion, E. Drug rash with eosinophilia and systemic symptoms vs toxic epidermal necrolysis: the dilemma of classifcation. Clin. Dermatol. 23, 311-314 (2005). (Pubitemid 40724465)
4. Bastuji-Garin, S., Fouchard, N., Bertocchi, M., Roujeau, J.C., Revuz, J. & Wolkenstein, P. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J. Invest. Dermatol. 115, 149-153 (2000). (Pubitemid 30637181)
5. Clarkson, A. & Choonara, I. Surveillance for fatal suspected adverse drug reactions in the UK. Arch. Dis. Child. 87, 462-466 (2002).
6. Zaccara, G., Franciotta, D. & Perucca, E. Idiosyncratic adverse reactions to antiepileptic drugs. Epilepsia 48, 1223-1244 (2007). (Pubitemid 47063067)
7. Uetrecht, J.P. Immune-mediated adverse drug reactions. Chem. Res. Toxicol. 22, 24-34 (2009).
8. Edwards, S.G., Hubbard, V., Aylett, S. & Wren, D. Concordance of primary generalised epilepsy and carbamazepine hypersensitivity in monozygotic twins. Postgrad. Med. J. 75, 680-681 (1999). (Pubitemid 29495605)
9. Chung, W.H. et al. Medical genetics: a marker for Stevens-johnson syndrome. Nature 428, 486 (2004).
10. Kamaliah, M.D., Zainal, D., Mokhtar, N. & Nazmi, N. Erythema multiforme, Stevens-johnson syndrome and toxic epidermal necrolysis in northeastern Malaysia. Int. J. Dermatol. 37, 520-523 (1998). (Pubitemid 28329047)
11. Roujeau, J.C. et al. Medication use and the risk of Stevens-johnson syndrome or toxic epidermal necrolysis. N. Engl. J. Med. 333, 1600-1607 (1995).
12. Hung, S.I., Chung, W.H. & Chen, Y.T. HLA-B genotyping to detect carbamazepine-induced Stevens-johnson syndrome: implications for personalizing medicine. Pers. Med. 2, 225-237 (2005).
13. Tassaneeyakul, W. et al. Association between HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in a Thai population. Epilepsia 51, 926-930 (2010).
14. Hung, S.L. et al. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet. Genomics 16, 297-306 (2006).
15. Wu, X.T. et al. Association between carbamazepine-induced cutaneous adverse drug reactions and the HLA-B*1502 allele among patients in central China. Epilepsy Behav. 19, 405-408 (2010).
16. Chang, C.C., Too, C.L., Murad, S. & Hussein, S. Association of HLA-B*1502 with carbamazepine-induced toxic epidermal necrolysis and Stevens-johnson syndrome in Malaysian population. 7th Asian-Oceanian Epilepsy Congress, Xiamen, China. (2008).
17. Mehta, T.Y. et al. Association of HLA-B*1502 allele and carbamazepine-induced Stevens-johnson syndrome among Indians. Indian J. Dermatol. Venereol. Leprol. 75, 579-582 (2009).
18. Kaniwa, N. et al. HLA-B locus in japanese patients with anti-epileptics and allopurinol-related Stevens-johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics 9, 1617-1622 (2008).
19. Alfrevic, A. et al. HLA-B locus in Caucasian patients with carbamazepine hypersensitivity. Pharmacogenomics 7, 813-818 (2006).
20. Lonjou, C. et al.; RegiSCAR Group. A marker for Stevens-johnson syndrome.: ethnicity matters. Pharmacogenomics J. 6, 265-268 (2006). (Pubitemid 44137953)
21. US Food and Drug Administration. Information for healthcare professionals: dangerous or even fatal skin reactions-Carbamazepine (marketed as Carbatrol, Equetro, Tegretol, And generics) FDA alert 12 December 2007, Updated 25 january 2010.
22. Ferrell, P.B. Jr & McLeod, H.L. Carbamazepine, HLA-B*1502 and risk of Stevens-johnson syndrome and toxic epidermal necrolysis: US FDA recommendations. Pharmacogenomics 9, 1543-1546 (2008).
23. Horton, R. et al. Gene map of the extended human MHC. Nat. Rev. Genet. 5, 889-899 (2004). (Pubitemid 39564252)
24. Hirsch, L.J. et al. Predictors of Lamotrigine-associated rash. Epilepsia 47, 318-322 (2006).
25. Man, C.B. et al. Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese. Epilepsia 48, 1015-1018 (2007). (Pubitemid 46763406)
26. Ikeda, H. et al. HLA class I markers in japanese patients with carbamazepine-induced cutaneous adverse reactions. Epilepsia 51, 297-300 (2010).
27. Alfrevic, A. et al. Serious carbamazepine-induced hypersensitivity reactions associated with the HSP70 gene cluster. Pharmacogenet. Genomics 16, 287-296 (2006).
28. Kazeema, G.R. et al. High-resolution HLA genotyping and severe cutaneous adverse reactions in lamotrigine-treated patients. Pharmacogenet Genomics 19, 661-665 (2009).
29. Chung, W.H., Hung, S.I. & Chen, Y.T. Human leukocyte antigens and drug hypersensitivity. Curr. Opin. Allergy Clin. Immunol. 7, 317-323 (2007).
30. Locharernkul, C., Shotelersuk, V. & Hirankarn, N. HLA-B* 1502 screening: time to clinical practice. Epilepsia 51, 936-938 (2010).